Home | Elsalys Biotech

Welcome to ElsaLys Biotech

ELSALYS BIOTECH is a pharmaceutical company which develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases.
Its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments.

Today ELSALYS BIOTECH is conducting 5 proprietary development programs including LEUKOTAC®, an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease.

The company is acting today in 3 main medical fields :

Acute Graft-vs-Host Disease

Immuno-oncology

ophthalmology (license option)

New Updates

Discover our latest news regarding our pipeline, our partnerships and more

View more news

New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases

Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30

Efficacy and safety are consistently demonstrated in several in vivo preclinical models
Anti-CD160 is a potent inhibitor of ocular v

ELSALYS BIOTECH ANNOUNCES THE REGISTRATION OF ITS DOCUMENT DE BASE IN THE CONTEXT OF ITS PROPOSED INITIAL PUBLIC OFFERING ON THE PARIS EURONEXT GROWTH® MARKET

Fri, 04/20/2018 - 08:30

Not to be distributed directly or indirectly in the United States, Canada, Australia or Japan

LEUKOTAC® takes next step in paediatric acute steroid-resistant GvHD

Thu, 04/05/2018 - 09:00

ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

Contactez Nous

Headquarters, R&D, Shipping Address : ElsaLys Biotech SA, 317 Avenue Jean Jaurès, 69007 Lyon Administrative site : ElsaLys Biotech SA, Pépinière de Hautepierre 8 avenue Dante, CS 70033 F-67087 Strasbourg contact@elsalysbiotech.com +33 (0)4 37 28 73 00